{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.7","value":"15.356"},{"groupId":"OG001","spread":"37.0","value":"15.922"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"1 year to \\< 10 years pediatric patients","id":"OG000","title":"Group 1"},{"description":"\\>= 10 years to \\<18 years pediatric patients","id":"OG001","title":"Group 2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1, had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 8 - Cycle 1 day 28","title":"Summary of Nilotinib Steady-state PK Parameters: CLF (Body Surface Area (BSA) Adjusted)","type":"PRIMARY","unitOfMeasure":"L/h/m^2)"}